Inhibition of CD146 lessens uveal melanoma progression through reducing angiogenesis and vasculogenic mimicry

Cell Oncol (Dordr). 2022 Aug;45(4):557-572. doi: 10.1007/s13402-022-00682-9. Epub 2022 Jun 18.

Abstract

Purpose: Anti-angiogenesis drug therapy is ineffective in treating uveal melanoma since it only targets angiogenesis leaving vasculogenic mimicry aside. There is no effective clinical strategy targeting vasculogenic mimicry, yet. We show here that CD146 is a novel target to inhibit uveal melanoma progression since it regulates both uveal melanoma angiogenesis and vasculogenic mimicry activity.

Methods: CD146 inhibition was achieved with its specific siRNAs or antibody AA98. Tube formation and migration of primary human retinal microvascular endothelial cells and tube-like structure formation, migration, invasion of uveal melanoma cells were evaluated after CD146 inhibition. The underlying mechanisms were investigated by Western blot and immunofluorescence. Finally, uveal melanoma cells were injected subretinally into the eyes of nude mice and AA98 was administrated. Tumor size was revealed by H&E staining, and angiogenesis and vasculogenic mimicry were evaluated with CD31-PAS staining.

Results: CD146 inhibition induced declines in tube formation and migration of primary human retinal microvascular endothelial cells and tube-like structure formation of uveal melanoma cells. CD146 mediated VEGFR/AKT/p38/NF-κB and FAK/VE-cadherin signal cascades were partially responsible for these biological effects. CD146 blockade by siRNA or AA98 also resulted in inhibition of migration and invasion as well as EMT process of uveal melanoma cells. The physiological relevance of such declines was confirmed by showing that AA98 treatment markedly suppressed the tumor growth, angiogenesis and vasculogenic mimicry induced by implantation of uveal melanoma cells into the eyes of nude mice.

Conclusions: CD146 is a novel mediator of both angiogenesis and vasculogenic mimicry in uveal melanoma. Its antibody AA98 has the potency to be developed as a new antibody drug for treating uveal melanoma. Our results warrant further assessment of CD146 as a potential target to improve therapeutic management of uveal melanoma in a clinical setting.

Keywords: AA98; Angiogenesis; CD146; Uveal melanoma; Vasculogenic mimicry.

MeSH terms

  • Animals
  • CD146 Antigen
  • Endothelial Cells* / pathology
  • Humans
  • Melanoma
  • Mice
  • Mice, Nude
  • Neovascularization, Pathologic / pathology
  • RNA, Small Interfering
  • Uveal Neoplasms* / blood supply
  • Uveal Neoplasms* / genetics
  • Uveal Neoplasms* / pathology

Substances

  • CD146 Antigen
  • RNA, Small Interfering

Supplementary concepts

  • Uveal melanoma